Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Basit Öğe Kaydı
dc.authoridYücel, Şebnem/0000-0001-6235-7927
dc.authoridalan, ozkan/0000-0002-6635-2012
dc.authoridKilickap, Saadettin/0000-0003-1637-7390
dc.authoridDoğan, İzzet/0000-0003-1018-1119
dc.authoridGürbüz, Mustafa/0000-0001-7680-4142
dc.authoridgülmez, ahmet/0000-0002-3353-344X
dc.authoridbilgin, burak/0000-0003-1717-8246
dc.authorwosidYalcin, Bulent/HIK-0062-2022
dc.authorwosidYücel, Şebnem/AAY-6737-2021
dc.authorwosidalan, ozkan/AAV-5044-2020
dc.authorwosidKilickap, Saadettin/AAP-3732-2021
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.authorwosidDoğan, İzzet/AAB-6635-2020
dc.authorwosidGürbüz, Mustafa/JAN-6390-2023
dc.contributor.authorBilgin, Burak
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorYucel, Sebnem
dc.contributor.authorCelik, Emir
dc.contributor.authorOzyukseler, Deniz Tataroglu
dc.contributor.authorAyhan, Murat
dc.contributor.authorBasoglu, Tugba
dc.date.accessioned2024-08-04T20:49:14Z
dc.date.available2024-08-04T20:49:14Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that investigate the efficacy and safety of the new generation TKIs in real-world patients. Thus, we aimed to compare the efficacy and safety of the afatinib, an irreversible inhibitor of ErbB family receptor, and first-generation TKIs in real-world patients. Materials and methods We included advanced nonsmall cell lung cancer (NSCLC) patients who had EGFR exon 19del mutation and treated with afatinib or first-generation TKIs as upfront treatment between 2016 and 2020. All patient's information was collected retrospectively. The study cohort was divided as afatinib arm and erlotinib/gefitinib arm. Results A total of 283 patients at the 24 oncology centers were included. The 89 and 193 of whom were treated with afatinib and erlotinib/gefitinib, respectively. After 12.9 months (mo) of follow-up, the median PFS was statistically longer in the afatinib arm than erlotinib/gefitinib arm (19.3 mo vs. 11.9 mo, p: 0.046) and the survival advantage was more profound in younger patients (< 65 years). The 24-mo overall survival rate was 76.1% and 49.5% in the afatinib arm and erlotinib/gefitinib arm, respectively. Although all-grade adverse event (AE) rates were similar between the two arms, grade 3-4 AE rates were higher in the afatinib arm (30.7% vs. 15.2%; p: 0.004). Discussion In our real-world study, afatinib has superior survival outcomes despite worse toxicity profile as inconsistent with clinical study results and it is the good upfront treatment option for younger patients and elderly patients who have good performance status.en_US
dc.identifier.doi10.1007/s00432-020-03501-6
dc.identifier.endpage2152en_US
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue7en_US
dc.identifier.pmid33433657en_US
dc.identifier.scopus2-s2.0-85099197058en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2145en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-020-03501-6
dc.identifier.urihttps://hdl.handle.net/11616/99714
dc.identifier.volume147en_US
dc.identifier.wosWOS:000608139100004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Cancer Research and Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAfatiniben_US
dc.subjectErlotiniben_US
dc.subjectExon 19 delen_US
dc.subjectGefitiniben_US
dc.subjectNSCLCen_US
dc.titleReal-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu